Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
STUDY DESIGN A single center case-control study evaluating the effect of Alutard SQ dog among 40 healthy men and women with moderate- to severe dog allergic patients. Recruited patients will be their own controls. STUDY OUTLINE The study will begin during the fall 2026. The trial will run over a one-year period. Patients will be asked to register allergic symptoms (base line), lungfunction and nasal breathing will be tested. Bloodsamples will be taken. Shortly after they will be provoked by entering a facility containing dogs. After 30 min provocation (contact with dog) they will again be asked to register allergic symptoms and undergo the same tests as before the treatment start. Allergic immunotherapy (allergy vaccination) with Alutard SQ dog is initiated according to a standard treatment plan and continued for one year. After one year the same procedure will be performed. Provocation will be performed by entering a facility containing dogs, followed by symptom registration and testing.
• \- The subject has given their written consent to participate in the trial.
• \- Age between 18-50.
• \- Moderate to severe allergic symptoms when in contact with dogs.
• \- Allergy confirmed with positive specific IgE to dog.
• \- Considered suitable by investigator to be prescribed Alutard SQ Dog in line with approved SPC.
• \- For female subjects of fertile age, adequate contraception should be used. A negative pregnancy test should be collected prior to inclusion.